Human AFP/FETA ORF/cDNA clone-Adenovirus plasmid (BC027881)
Cat. No.: pGMAP000189
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days
Pre-made Human AFP/FETA adenoviral expression plasmid for AFP adenovirus packaging, AFP adenovirus.
Our GM-Adenovirus vector is optimized with the GMVC-modified Adeasy adenovirus packaging system. Find more about the GMVC-modified adenovirus packaging system.
Go to
AFP/FETA products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product Description
Catalog ID | pGMAP000189 |
Gene Name | AFP |
Accession Number | BC027881 |
Gene ID | 174 |
Species | Human |
Product Type | Adenovirus plasmid (overexpression) |
Insert Length | 1830 bp |
Gene Alias | FETA |
Fluorescent Reporter | GFP |
Mammalian Cell Selection | Null |
Fusion Tag | 3xflag (C-Terminal) |
Promoter | EF1 |
Resistance | Kanamycin |
ORF Nucleotide Sequence | ATGAAGTGGGTGGAATCAATTTTTTTAATTTTCCTACTAAATTTTACTGAATCCAGAACACTGCATAGAAATGAATATGGAATAGCTTCCATATTGGATTCTTACCAATGTACTGCAGAGATAAGTTTAGCTGACCTGGCTACCATATTTTTTGCCCAGTTTGTTCAAGAAGCCACTTACAAGGAAGTAAGCAAAATGGTGAAAGATGCATTGACTGCAATTGAGAAACCCACTGGAGATGAACAGTCTTCAGGGTGTTTAGAAAACCAGCTACCTGCCTTTCTGGAAGAACTTTGCCATGAGAAAGAAATTTTGGAGAAGTACGGACATTCAGACTGCTGCAGCCAAAGTGAAGAGGGAAGACATAACTGTTTTCTTGCACACAAAAAGCCCACTCCAGCATCGATCCCACTTTTCCAAGTTCCAGAACCTGTCACAAGCTGTGAAGCATATGAAGAAGACAGGGAGACATTCATGAACAAATTCATTTATGAGATAGCAAGAAGGCATCCCTTCCTGTATGCACCTACAATTCTTCTTTGGGCTGCTCGCTATGACAAAATAATTCCATCTTGCTGCAAAGCTGAAAATGCAGTTGAATGCTTCCAAACAAAGGCAGCAACAGTTACAAAAGAATTAAGAGAAAGCAGCTTGTTAAATCAACATGCATGTGCAGTAATGAAAAATTTTGGGACCCGAACTTTCCAAGCCATAACTGTTACTAAACTGAGTCAGAAGTTTACCAAAGTTAATTTTACTGAAATCCAGAAACTAGTCCTGGATGTGGCCCATGTACATGAGCACTGTTGCAGAGGAGATGTGCTGGATTGTCTGCAGGATGGGGAAAAAATCATGTCCTACATATGTTCTCAACAAGACACTCTGTCAAACAAAATAACAGAATGCTGCAAACTGACCACGCTGGAACGTGGTCAATGTATAATTCATGCAGAAAATGATGAAAAACCTGAAGGTCTATCTCCAAATCTAAACAGGTTTTTAGGAGATAGAGATTTTAACCAATTTTCTTCAGGGGAAAAAAATATCTTCTTGGCAAGTTTTGTTCATGAATATTCAAGAAGACATCCTCAGCTTGCTGTCTCAGTAATTCTAAGAGTTGCTAAAGGATACCAGGAGTTATTGGAGAAGTGTTTCCAGACTGAAAACCCTCTTGAATGCCAAGATAAAGGAGAAGAAGAATTACAGAAATACATCCAGGAGAGCCAAGCATTGGCAAAGCGAAGCTGCGGCCTCTTCCAGAAACTAGGAGAATATTACTTACAAAATGCGTTTCTCGTTGCTTACACAAAGAAAGCCCCCCAGCTGACCTCGTCGGAGCTGATGGCCATCACCAGAAAAATGGCAGCCACAGCAGCCACTTGTTGCCAACTCAGTGAGGACAAACTATTGGCCTGTGGCGAGGGAGCGGCTGACATTATTATCGGACACTTATGTATCAGACATGAAATGACTCCAGTAAACCCTGGTGTTGGCCAGTGCTGCACTTCTTCATATGCCAACAGGAGGCCATGCTTCAGCAGCTTGGTGGTGGATGAAACATATGTCCCTCCTGCATTCTCTGATGACAAGTTCATTTTCCATAAGGATCTGTGCCAAGCTCAGGGTGTAGCGCTGCAAACGATGAAGCAAGAGTTTCTCATTAACCTTGTGAAGCAAAAGCCACAAATAACAGAGGAACAACTTGAGGCTGTCATTGCAGATTTCTCAGGCCTGTTGGAGAAATGCTGCCAAGGCCAGGAACAGGAAGTCTGCTTTGCTGAAGAGGGACAAAAACTGATTTCAAAAACTCGTGCTGCTTTGGGAGTTTAA |
ORF Protein Sequence | MKWVESIFLIFLLNFTESRTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDALTAIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQVPEPVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVTKELRESSLLNQHACAVMKNFGTRTFQAITVTKLSQKFTKVNFTEIQKLVLDVAHVHEHCCRGDVLDCLQDGEKIMSYICSQQDTLSNKITECCKLTTLERGQCIIHAENDEKPEGLSPNLNRFLGDRDFNQFSSGEKNIFLASFVHEYSRRHPQLAVSVILRVAKGYQELLEKCFQTENPLECQDKGEEELQKYIQESQALAKRSCGLFQKLGEYYLQNAFLVAYTKKAPQLTSSELMAITRKMAATAATCCQLSEDKLLACGEGAADIIIGHLCIRHEMTPVNPGVGQCCTSSYANRRPCFSSLVVDETYVPPAFSDDKFIFHKDLCQAQGVALQTMKQEFLINLVKQKPQITEEQLEAVIADFSGLLEKCCQGQEQEVCFAEEGQKLISKTRAALGV |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
---|---|---|
Biosimilar | GMP-Bios-INN-1053 | Pre-Made Yttrium (90Y) Tacatuzumab Tetraxetan Biosimilar, Radiolabelled Antibody, Anti-Afp Antibody: Anti-AFPD/FETA/HPAFP therapeutic antibody |
Target Antibody | GM-Tg-g-T10828-Ab | Anti-FETA/ AFP/ AFPD functional antibody |
Target Antigen | GM-Tg-g-T10828-Ag | AFP protein |
ORF Viral Vector | pGMAP000189 | Human AFP Adenovirus plasmid |
ORF Viral Vector | vGMAP000189 | Human AFP Adenovirus particle |
Target information
Target ID | GM-T10828 |
Target Name | AFP |
Gene ID | 174, 11576, 704786, 101082056, 403551, 506011, 100034185 |
Gene Symbol and Synonyms | AFP,AFPD,FETA,HPAFP |
Uniprot Accession | P02771 |
Uniprot Entry Name | FETA_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Therapeutics Target, Diagnostics Biomarker, Immuno-oncology Target, INN Index |
Disease | Ovary Cancer, Hepatocellular carcinoma, malformations and congenital abnormalities, neural tube defects, Ovarian cancer, Pancreoblastoma, Teratoma, Teratoma: oral cavity, testicular germ cell tumors, Tumors: Desmoplastic small round cell tumor (DSRCT), Tumors: endodermal sinus tumor, Tumors: Epithelial liver tumors, Tumors: Intracranial germ cell, Germ cell tumors (GCT), Down's syndrome, Cancer: Germ cell tumors, Hepatic cancer, hepatocellular carcinoma, hepatocellular cancer, liver diseases |
Gene Ensembl | ENSG00000081051 |
Target Classification | Checkpoint-Immuno Oncology |
This gene encodes alpha-fetoprotein, a major plasma protein produced by the yolk sac and the liver during fetal life. Alpha-fetoprotein expression in adults is often associated with hepatocarcinoma and with teratoma, and has prognostic value for managing advanced gastric cancer. However, hereditary persistance of alpha-fetoprotein may also be found in individuals with no obvious pathology. The protein is thought to be the fetal counterpart of serum albumin, and the alpha-fetoprotein and albumin genes are present in tandem in the same transcriptional orientation on chromosome 4. Alpha-fetoprotein is found in monomeric as well as dimeric and trimeric forms, and binds copper, nickel, fatty acids and bilirubin. The level of alpha-fetoprotein in amniotic fluid is used to measure renal loss of protein to screen for spina bifida and anencephaly. [provided by RefSeq, Oct 2019]
About GMVC
GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.